-transparent.png){kind=logo}
Although beta-agonists remain an important aspect of the treatment of asthma, their role has recently been questioned. Salmeterol has recently been developed as a beta-agonist with prolonged bronchodilator action. Using lucigenin-enhanced chemiluminescence, we have shown that salmeterol inhibits this aspect of phagocyte function in vitro in a concentration-dependent manner. However, salmeterol differs from classical beta 2-agonists in that at concentrations between 10(-5) and 10(-3) mol/L, its effects on phagocytes cannot be completely reversed by washing the cells or by propranolol. The effects on phagocytes may not therefore be explicable on the basis of beta-adrenergic mechanisms alone.
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1982,
Allergologia et immunopathologia,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1979,
Advances in experimental medicine and biology,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1980,
Archivum immunologiae et therapiae experimentalis,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1980,
Archivum immunologiae et therapiae experimentalis,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1986,
Beitrage zu Infusionstherapie und klinische Ernahrung,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 2000,
Luminescence : the journal of biological and chemical luminescence,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1981,
Archivum immunologiae et therapiae experimentalis,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
January 1987,
International journal of tissue reactions,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
April 1982,
Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology,
L Ramage, and
A L Blair, and
I A Cree, and
D P Dhillon
October 1978,
Infection and immunity,
